Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study

BACKGROUND: Erythropoietic protoporphyria (EPP) is an ultra-rare genetic disorder (prevalence 1:150`000) characterized by instant painful phototoxic burn reactions in skin exposed to visible light. Afamelanotide is the first clinically tested therapy effectively increasing the time EPP patients can...

Descripción completa

Detalles Bibliográficos
Autores principales: Barman-Aksözen, Jasmin, Nydegger, Michèle, Schneider-Yin, Xiaoye, Minder, Anna-Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437008/
https://www.ncbi.nlm.nih.gov/pubmed/32811524
http://dx.doi.org/10.1186/s13023-020-01505-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437008/
https://www.ncbi.nlm.nih.gov/pubmed/32811524
http://dx.doi.org/10.1186/s13023-020-01505-6

Ejemplares similares